Table 6

Clinical and Angiographic Outcomes After Percutaneous Treatment of DES ISR

Study/First Author (Ref. #)YearNo. of LesionsType of DESFollow-up DurationTLRAngiographic RestenosisTreatment Modalities Used
Randomized trial
 ISAR-DESIRE 22010450SES6–8 months16.7%18.0%PES 50%, SES 50%
Observational studies
 Lemos et al. (68)200424SES9.3 months20.8%42.9%BA 11%, BMS 4%, PES 41%, SES 44%
 Moussa et al. (70)200622SES12 months23.0%N/ABA 13.5%, BMS 82%, VBT 4.5%
 Lee et al. (67)2006140SES7.2 ± 1.8 months14.0%N/APES 100%
 Torguson et al. (71)2006111PES 22%, SES 78%8 months13.5%N/APES 11%, SES 34%, VBT 55%
 Kim et al. (66)200658PES 47%, SES 53%12 months5.2%16.7%BA 19%, SES 57%, VBT 24%
 Cosgrave et al. (64)2006250PES 34%, SES 66%9 months14.4%28.4%BA 38%, DES 62%
 Mishkel et al. (69)2007108SES, PES15 ± 6 months28.2%N/ABA 1%, BMS 18%, DES 80%, VBT 1%
 Garg et al. (65)2007116SES, PES12 months15.7%N/ASES, PES
 Solinas et al. (20)2008152PES 22%, SES 78%12 months8.3%N/ABA 16%, DES 84%
 Bonello et al. (72)2008122N/A12 months10.0%N/AVBT
 Chatani et al. (73)2009140SES2 yrs33.7%32.5%OTHER 35%, PES 22%, SES 43%
 Steinberg et al. (22)2009119N/A12 months22.2%*N/ADES
 Rathore et al. (23)2010351SES9 months37.0%*41.1%BA 67%, BMS 1%, PES 5%, SES 17%
 Tagliareni et al. (75)2010252PES 39%, SES 57%, ZES 4%23 ± 10 months11.8%N/ABA 53%, DES 47%
 Singh et al. (74)2010319N/A3.2 yrs15.0%N/AN/A

BA = balloon angioplasty; DES = drug-eluting stent(s); TLR = target lesion revascularization; VBT = vascular brachytherapy; ZES = zotarolimus-eluting stent(s); other abbreviations as in Table 5.

  • * These rates are for target vesselrevascularization.